An observation study of pancreatic endocrine secretion after glucagon infusion on the patients that were operated with a subtotal pancreatectomy

An observation study of pancreatic endocrine secretion after glucagon infusion on the patients that were operated with a subtotal pancreatectomy - An observation study of pancreatic endocrine secretion on the patients after tumor removal by subtotal pancreatectomy

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000004644

Enrollment

100

Registered

2010-12-02

Start date

2010-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic biliary tract disease including malignant disorders is planned a subtotal pancreatectomy

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (a) Patients were underwent subtotal pancreatectomy. (b) Patients are outpatients or inpatients (c) Patients need anti-diabetic agents after subtotal pancreatectomy. (d) Patients with a therapy of diabetes mellitus before subtotal pancreatectomy.

Exclusion criteria

Exclusion criteria: (a) Patients with a history of total pancreatectomy. (b) Patients with insulin-dependent diabetes mellitus.(Fatigue serum C-peptide under 0.5 ng/ml or 24hr C-peptide under 20 microg/day) (c) Patients with a history of severe cardiovascular or cerebrovascular disease or renal failure. (d) Patients have contraindication of glucagon. (e) Patients with severe liver damage. (f) Patients are pregnant or patients breast-feeding, potentially pregnant. (g) Patients who are diagnosed to be ineligible by the investigator.

Design outcomes

Primary

Measure	Time frame
Delta C-peptide in glucagon injection. (delta C-peptide = max C-peptide - base C-peptide) Observation of the mean of delta C-peptide from before to the end of study.	—

Countries

Japan

Contacts

Public ContactTsuguka Shiwa

Hiroshima University Hospital Department of Endocrinology and Diabetes mellitus

tsuguka@hiroshima-u.ac.jp082-257-5198

Outcome results